{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T07:18:50Z","timestamp":1761808730065,"version":"3.44.0"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"38","license":[{"start":{"date-parts":[[2025,9,19]],"date-time":"2025-09-19T00:00:00Z","timestamp":1758240000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,9,19]]},"abstract":"<jats:p>Glucagon-like peptide-1 receptor (GLP1R) agonists (GLP1RAs) are widely used in type 2 diabetes mellitus (T2DM) management due to their glycemic and cardiorenal benefits, yet emerging evidence suggests potential renal adverse effects, particularly tubulo-interstitial nephritis (TIN). We conducted a 2-sample Mendelian randomization (MR) analysis to investigate causal relationships between GLP1RA use and TIN risks. Genetic proxies for GLP1RA effects were derived from cis-eQTLs for GLP1R. Proteome-wide MR and mediation analyses with UK Biobank Pharma Proteomics Project data were also used to identify mediating plasma proteins and biological pathways. MR analyses showed a significant causal link between GLP1RA use and chronic tubulo-interstitial nephritis (CTIN; OR\u2005=\u20052.32, 95% CI\u2005=\u20051.39\u20133.85, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.001), with no significant association for acute tubulo-interstitial nephritis (ATIN; OR\u2005=\u20050.93, 95% CI\u2005=\u20050.83\u20131.04, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.216). Colocalization analysis strongly supported the MR findings, showing a high posterior probability of shared genetic variants between GLP1R expression and CTIN (PP.H4\u2005=\u20050.99). Mediation analysis identified 4 plasma proteins (HYAL1, NMNAT1, IL12RB2, and DPP6) as partial mediators of the effect. Genetic evidence from this study indicated an association between GLP1R agonists and higher risk of chronic tubulo-interstitial nephritis. Potential risks need to be evaluated when prescribing GLP1RAs in in clinical practice.<\/jats:p>","DOI":"10.1097\/md.0000000000044742","type":"journal-article","created":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T20:01:05Z","timestamp":1758571265000},"page":"e44742","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Genetically proxied glucagon-like peptide-1 receptor agonist is associated with risk of tubulo-interstitial nephritis: A network Mendelian randomization study"],"prefix":"10.1097","volume":"104","author":[{"given":"Xu-Chun","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Nephrology, Jinhua Hospital Affiliated to Zhejiang University School of Medicine, Zhejiang Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang-Zhong","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Jinhua Hospital Affiliated to Zhejiang University School of Medicine, Zhejiang Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Ying","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Jinhua Hospital Affiliated to Zhejiang University School of Medicine, Zhejiang Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting-Ting","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Jinhua Hospital Affiliated to Zhejiang University School of Medicine, Zhejiang Province, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-6432-6322","authenticated-orcid":false,"given":"Hua-Ying","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Jinhua Hospital Affiliated to Zhejiang University School of Medicine, Zhejiang Province, China."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250928","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1053\/j.ackd.2021.04.002","article-title":"Glucagon-like peptide-1 receptor agonists-use in clinical practice.","volume":"28","author":"Trico","year":"2021","journal-title":"Adv Chronic Kidney Dis"},{"key":"R2-20250928","doi-asserted-by":"crossref","first-page":"258","DOI":"10.3803\/EnM.2016.31.2.258","article-title":"Cardiovascular effects of glucagon-like Peptide-1 receptor agonists.","volume":"31","author":"Kang","year":"2016","journal-title":"Endocrinol Metab (Seoul)"},{"key":"R3-20250928","doi-asserted-by":"crossref","first-page":"101641","DOI":"10.1016\/j.diabet.2025.101641","article-title":"Renoprotective mechanisms of glucagon-like peptide-1 receptor agonists.","volume":"51","author":"J","year":"2025","journal-title":"Diabetes Metab"},{"key":"R4-20250928","doi-asserted-by":"crossref","first-page":"e13609","DOI":"10.1111\/1753-0407.13609","article-title":"Glucagon-like peptide-1 receptor agonists and kidney outcomes.","volume":"16","author":"MacIsaac","year":"2024","journal-title":"J Diabetes"},{"key":"R5-20250928","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists.","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev Diabet Stud"},{"key":"R6-20250928","doi-asserted-by":"crossref","first-page":"sfae250","DOI":"10.1093\/ckj\/sfae250","article-title":"Semaglutide-associated kidney injury.","volume":"17","author":"Begum","year":"2024","journal-title":"Clin Kidney J"},{"key":"R7-20250928","doi-asserted-by":"crossref","first-page":"a040501","DOI":"10.1101\/cshperspect.a040501","article-title":"Mendelian randomization: concepts and scope.","volume":"12","author":"Richmond","year":"2022","journal-title":"Cold Spring Harb Perspect Med"},{"key":"R8-20250928","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1001\/jama.2017.17219","article-title":"Mendelian randomization.","volume":"318","author":"Emdin","year":"2017","journal-title":"JAMA"},{"key":"R9-20250928","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1001\/jama.2021.18236","article-title":"Strengthening the reporting of observational studies in epidemiology using mendelian randomization: the STROBE-MR statement.","volume":"326","author":"Skrivankova","year":"2021","journal-title":"JAMA"},{"key":"R10-20250928","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1038\/s41588-021-00913-z","article-title":"Large-scale cis- and trans-eQTL analyses identify thousands of genetic loci and polygenic scores that regulate blood gene expression.","volume":"53","author":"Vosa","year":"2021","journal-title":"Nat Genet"},{"key":"R11-20250928","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1007\/s00125-023-05925-4","article-title":"Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis.","volume":"66","author":"Yarmolinsky","year":"2023","journal-title":"Diabetologia"},{"key":"R12-20250928","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1093\/ije\/dyq151","article-title":"Power and instrument strength requirements for Mendelian randomization studies using multiple genetic variants.","volume":"40","author":"Pierce","year":"2011","journal-title":"Int J Epidemiol"},{"key":"R13-20250928","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/s41586-023-06592-6","article-title":"Plasma proteomic associations with genetics and health in the UK Biobank.","volume":"622","author":"Sun","year":"2023","journal-title":"Nature"},{"key":"R14-20250928","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/s41588-020-0682-6","article-title":"Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases.","volume":"52","author":"Zheng","year":"2020","journal-title":"Nat Genet"},{"key":"R15-20250928","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1093\/ije\/dyv080","article-title":"Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression.","volume":"44","author":"Bowden","year":"2015","journal-title":"Int J Epidemiol"},{"key":"R16-20250928","doi-asserted-by":"crossref","first-page":"e1007081","DOI":"10.1371\/journal.pgen.1007081","article-title":"Orienting the causal relationship between imprecisely measured traits using GWAS summary data.","volume":"13","author":"Hemani","year":"2017","journal-title":"PLoS Genet"},{"key":"R17-20250928","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1038\/s41562-022-01412-9","article-title":"Bidirectional two-sample Mendelian randomization analysis identifies causal associations between relative carbohydrate intake and depression.","volume":"6","author":"Yao","year":"2022","journal-title":"Nat Hum Behav"},{"key":"R18-20250928","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1037\/1082-989X.7.1.83","article-title":"A comparison of methods to test mediation and other intervening variable effects.","volume":"7","author":"MacKinnon","year":"2002","journal-title":"Psychol Methods"},{"key":"R19-20250928","doi-asserted-by":"crossref","first-page":"104494","DOI":"10.1016\/j.ebiom.2023.104494","article-title":"Therapeutic targets for inflammatory bowel disease: proteome-wide Mendelian randomization and colocalization analyses.","volume":"89","author":"Chen","year":"2023","journal-title":"EBioMedicine"},{"key":"R20-20250928","doi-asserted-by":"crossref","first-page":"828","DOI":"10.2337\/dc22-1385","article-title":"Gastrointestinal consequences of type 2 diabetes mellitus and impaired glycemic homeostasis: a mendelian randomization study.","volume":"46","author":"Chen","year":"2023","journal-title":"Diabetes Care"},{"key":"R21-20250928","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/s41467-020-20885-8","article-title":"A fast and efficient colocalization algorithm for identifying shared genetic risk factors across multiple traits.","volume":"12","author":"Foley","year":"2021","journal-title":"Nat Commun"},{"key":"R22-20250928","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2020.07.008","article-title":"Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design.","volume":"229","author":"Ryan","year":"2020","journal-title":"Am Heart J"},{"key":"R23-20250928","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.kint.2023.09.029","article-title":"Glucagon-like peptide-1 receptor signaling modifies the extent of diabetic kidney disease through dampening the receptor for advanced glycation end products-induced inflammation.","volume":"105","author":"Sourris","year":"2024","journal-title":"Kidney Int"},{"key":"R24-20250928","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1464-5491.2012.03738.x","article-title":"Acute tubulointerstitial nephritis following treatment with exenatide.","volume":"30","author":"Nandakoban","year":"2013","journal-title":"Diabet Med"},{"key":"R25-20250928","doi-asserted-by":"crossref","first-page":"508","DOI":"10.2337\/cd21-0142","article-title":"A case of dulaglutide-induced acute interstitial nephritis after many years of treatment with an alternate GLP-1 receptor agonist.","volume":"40","author":"Komala","year":"2022","journal-title":"Clin Diabetes"},{"key":"R26-20250928","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1038\/s41591-024-03412-w","article-title":"Mapping the effectiveness and risks of GLP-1 receptor agonists.","volume":"31","author":"Xie","year":"2025","journal-title":"Nat Med"},{"key":"R27-20250928","doi-asserted-by":"crossref","first-page":"S73","DOI":"10.1016\/S1262-3636(08)73398-6","article-title":"GLP-1 receptor signaling: effects on pancreatic beta-cell proliferation and survival.","volume":"34","author":"Buteau","year":"2008","journal-title":"Diabetes Metab"},{"key":"R28-20250928","doi-asserted-by":"crossref","first-page":"24195","DOI":"10.1074\/jbc.M411913200","article-title":"Hyaluronan fragments induce endothelial cell differentiation in a CD44- and CXCL1\/GRO1-dependent manner.","volume":"280","author":"Takahashi","year":"2005","journal-title":"J Biol Chem"},{"key":"R29-20250928","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1146\/annurev.cellbio.23.090506.123337","article-title":"Hyaluronan in tissue injury and repair.","volume":"23","author":"Jiang","year":"2007","journal-title":"Annu Rev Cell Dev Biol"},{"key":"R30-20250928","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1046\/j.1523-1755.2001.0590051739.x","article-title":"Regulation of renal proximal tubular epithelial cell hyaluronan generation: implications for diabetic nephropathy.","volume":"59","author":"Jones","year":"2001","journal-title":"Kidney Int"},{"key":"R31-20250928","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1074\/jbc.RA119.010571","article-title":"A nicotinamide phosphoribosyltransferase-GAPDH interaction sustains the stress-induced NMN\/NAD(+) salvage pathway in the nucleus.","volume":"295","author":"Grolla","year":"2020","journal-title":"J Biol Chem"},{"key":"R32-20250928","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.3390\/ijms23073458","article-title":"NAD(+) Anabolism disturbance causes glomerular mesangial cell injury in diabetic nephropathy.","volume":"23","author":"Li","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R33-20250928","doi-asserted-by":"crossref","first-page":"10484","DOI":"10.3390\/ijerph181910484","article-title":"The mediation effects of aluminum in plasma and dipeptidyl peptidase like protein 6 (DPP6) polymorphism on renal function via genome-wide typing association.","volume":"18","author":"Chen","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"R34-20250928","doi-asserted-by":"crossref","first-page":"211","DOI":"10.3390\/genes11020211","article-title":"Inhibition of angiotensin-converting enzyme ameliorates renal fibrosis by mitigating DPP-4 level and restoring antifibrotic microRNAs.","volume":"11","author":"Srivastava","year":"2020","journal-title":"Genes (Basel)"},{"key":"R35-20250928","doi-asserted-by":"crossref","first-page":"583","DOI":"10.5604\/17322693.1009653","article-title":"[The role of TGF-beta-related signal transduction pathways in pathogenesis of epithelial-mesenchymal transition as a key element in cancer development and progression].","volume":"66","author":"Pieniazek","year":"2012","journal-title":"Postepy Hig Med Dosw (Online)"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044742","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:01:53Z","timestamp":1759046513000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000044742"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,19]]},"references-count":35,"journal-issue":{"issue":"38","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000044742","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2025,9,19]]},"assertion":[{"value":"2025-05-15","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-25","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}